Why Starting Dose Matters for Wegovy vs Mounjaro Success
Understanding 1.7mg Wegovy vs Mounjaro Starting Requirements
When comparing 1.7mg Wegovy vs Mounjaro, it's crucial to understand that 1.7mg represents weeks 13-16 of the Wegovy escalation protocol, not a starting point. Both prescription-only medicines require careful dose escalation to minimise side effects and optimise effectiveness. Wegovy's structured 16-week escalation begins at 0.25mg, progressing through 0.5mg, 1mg, and 1.7mg before reaching the 2.4mg maintenance dose. This graduated approach allows your body to adapt to semaglutide's appetite-suppressing effects whilst reducing the likelihood of gastrointestinal side effects.
Mounjaro follows a similar escalation pattern but uses different doses due to tirzepatide's dual-receptor mechanism. The key difference lies in how these medicines work - Wegovy targets GLP-1 receptors exclusively, whilst Mounjaro activates both GLP-1 and GIP receptors. Both medications must be prescribed alongside a reduced-calorie diet and increased physical activity, and neither can be started at higher doses regardless of previous experience with weight management medications.
Wegovy vs Mounjaro Pricing and Value Comparison
Your 1.7mg Wegovy vs Mounjaro decision begins with the starter dose pricing at EverydayMeds. Wegovy 0.25mg costs £79.99 for new customers using code FIRST40 at checkout, representing exceptional value for a prescription-only medicine that took over a decade to develop. Our Intro Duo bundle (0.25mg + 0.5mg) provides your first two months of treatment for £169.99, ensuring continuity without additional ordering. Returning customers benefit from code DOSE25 for ongoing savings throughout their weight management journey.
The path to 1.7mg Wegovy requires investment in proper dose escalation - skipping doses isn't medically advisable and may increase side effects significantly. Our Progress Trio bundle (0.5mg, 1mg, 1.7mg) costs £369.99 and covers weeks 5-16 of your treatment. Mounjaro pricing follows a different structure due to its distinct dosing schedule, but both options represent significant value when considering the clinical evidence and manufacturing complexity of these innovative medications from our GPhC-registered pharmacy #9012878.
Clinical Evidence: 1.7mg Wegovy vs Mounjaro Effectiveness
The STEP clinical trial programme demonstrates Wegovy's effectiveness, with STEP 1 showing approximately 15% average weight loss at 68 weeks versus 2.4% with placebo. Patients taking Wegovy alongside diet and exercise in STEP 2 achieved around clinically studied weight loss, whilst STEP 3 participants reached approximately 16% with intensive behavioural therapy. The SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events, highlighting benefits beyond weight management.
Mounjaro's clinical evidence comes from the SURMOUNT trial series, though comparing trial results directly isn't appropriate due to different study designs and patient populations. Both 1.7mg Wegovy and Mounjaro represent evidence-based approaches to weight management when used as prescribed by qualified healthcare professionals. The choice between these medications depends on individual patient factors, medical history, and prescriber assessment rather than superior efficacy claims.
How Wegovy's Semaglutide Mechanism Works
Understanding how Wegovy works helps explain why 1.7mg represents an important milestone in your treatment journey. Semaglutide mimics GLP-1, a natural hormone released when you eat that signals fullness to your brain. By activating GLP-1 receptors, Wegovy slows gastric emptying, meaning food stays in your stomach longer and you feel satisfied after smaller portions. The medication also works directly on appetite centres in your brain, potentially reducing food cravings and the psychological drive to eat. This dual mechanism - both peripheral and central - explains why proper dose escalation to 1.7mg is essential for optimal effectiveness. The higher dose provides more sustained receptor activation, supporting continued weight management as your body adapts to the treatment.
EverydayMeds Ordering Process for Wegovy Starter Doses
Beginning your Wegovy journey requires completing our 3-minute online clinical assessment, covering medical history, current medications, and weight management goals. Our qualified prescribers review applications within 3 working days (express 24-hour service available), ensuring safe prescribing practices and appropriate patient selection. Once approved, your starter dose ships via next-day cold-chain delivery, maintaining the required 2-8°C temperature throughout transit. All Wegovy pens arrive in temperature-controlled packaging with monitoring indicators, guaranteeing medication integrity from our GPhC-registered facility to your door. Our clinical team remains available for ongoing support as you progress from 0.25mg towards your 1.7mg milestone dose.
Storage and Practical Considerations: Wegovy vs Mounjaro
Wegovy offers significant practical advantages when comparing storage requirements with Mounjaro, particularly important for the 1.7mg dose and beyond. Once removed from refrigeration, Wegovy maintains stability for 6 weeks at room temperature below 30°C, compared to Mounjaro's 21-day limit. This extended room temperature stability makes Wegovy ideal for travel, work situations, or lifestyle flexibility without refrigeration access. The FlexTouch pen design provides precise dosing with clear visual confirmation, whilst the weekly injection schedule fits easily into most routines. Proper storage becomes increasingly important as you progress to 1.7mg and maintenance dosing, where treatment consistency directly impacts long-term success. Both medications require careful handling, but Wegovy's storage advantage often influences patient preference for sustained weight management programmes.
Why 1.7mg Wegovy vs Mounjaro Starter Dose Planning Matters
Planning your progression to 1.7mg Wegovy requires understanding why you cannot start at higher doses, even if switching from other weight management approaches. The dose escalation protocol exists for patient safety - starting too high significantly increases nausea, vomiting, and discontinuation rates. Clinical studies specifically tested the current escalation schedule to balance effectiveness with tolerability. Your body needs time to adapt to GLP-1 receptor activation, with each dose increase building tolerance for the next level.
This gradual approach means reaching 1.7mg takes 13-16 weeks, but patients who follow the prescribed escalation achieve better long-term outcomes than those attempting shortcuts. The investment in proper dose escalation pays dividends when you reach maintenance therapy, with reduced side effects and sustained appetite control. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which option aligns best with your medical profile and lifestyle preferences.
Starting Your Wegovy Journey: From 0.25mg to 1.7mg Success
Your decision between 1.7mg Wegovy vs Mounjaro begins today with the 0.25mg starter dose at £79.99, using code FIRST40 for new customers or DOSE25 for returning patients. Complete our clinical assessment at https://everydaymeds.co.uk/products/wegovy-0-25mg to begin your medically-supervised weight management journey. Our qualified prescribers ensure safe, appropriate prescribing aligned with MHRA licensing and NICE guidelines for optimal patient outcomes. With next-day delivery and ongoing clinical support, EverydayMeds provides the foundation for successful progression through each dose milestone. Remember that weight management requires commitment beyond medication - combining Wegovy with reduced-calorie diet and increased physical activity maximises your chances of reaching and maintaining your health goals throughout the treatment programme.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
